retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Triple hormone receptor agonist retatrutide

WC : Waist circumference

BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia

Blum about adjusting my dose, says Turner

Until oral GLP-1 formulations become widely available and proven for weight loss, Qsymia remains the strongest oral option

Understanding this bidirectional relationship is important for developing more effective, holistic treatment approaches that address both the psychological and physiological aspects of these intertwined health challenges

The differentiator is pathway-level genetic insight context that most telehealth-only programs like Mochi Health do not offer alongside the medication itself